All lobbying filings

CAPITOL HILL CONSULTING GROUP

CAPITOL HILL CONSULTING GROUP filed a Q3 report for TEVA PHARMACEUTICALS USA on October 20, 2026, reporting $20,000 in lobbying income.

Lobbying for TEVA PHARMACEUTICALS USA · Generic and biosimilar manufacturer.

All filings by CAPITOL HILL CONSULTING GROUP · Everything TEVA PHARMACEUTICALS USA has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Income

$20,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 3

BRIAN SUTTER

Previously held: Staff Dir. W&M Health subcommittee, Chairman Dave Camp April'13-Dec'14. Professional Staff, W&M Health subcommittee, Chairman Dave Camp, Jan'11-April'13. Leg Dir. Rep Dave Camp, May'08-Jan'11. Leg Asst Rep Dave Camp, Feb'03-May'08. Staff Ast July'02
EMILY ELIZABETH WILKINSON-HOLLAND

Previously held: Staff -Rep. Price (2010-11), LA: Rep. Grimm (2011-12), Rep. Black (2012-13), Sen.Vitter (2013-2015), Sen. Heller (2015-17), Policy Adv. to the Sec.- Dept of HHS (3/2017-8/2017), Sr Advisor to Administrator - Ctrs for Medicare & Medicaid (8/17- 5/19)
CHRISTOPHER DAVIS New on this filing

Previously held: Staff Assistant, Legislative Assistant, Senior Legislative Assistant, and Legislative Director - Rep. Rick Boucher (2006-2011)

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Health Issues

Issues surrounding US Pharmaceutical supply chain. Issues surrounding the generic drug and biosimilar user free agreements. Issues surrounding the regulation of complex generic drugs. Issues related to Inflation Reduction Act. Issues related to generic drug review.

Trade (domestic/foreign)

Issues related to potential tariffs on generic drugs.

Medicare/Medicaid

Issues surrounding Medicare reimbursement of generic drugs and biosimilars. Issues relating to the impact of prescription drug negotiation on generic drugs. Issues related to drug shortages. Issues related to drug pricing including drug negotiation.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.